Skip to main content
. Author manuscript; available in PMC: 2016 Apr 15.
Published in final edited form as: J Acquir Immune Defic Syndr. 2015 Apr 15;68(5):554–561. doi: 10.1097/QAI.0000000000000510

Table 2.

Delivery of the medication assisted treatment for opioid dependence

Initiated BUP/NX induction Completed induction Completed detoxification Weekly counseling1 (≥75% sessions weeks 1–12) Monthly counseling1 (≥75% sessions months 4–12)
Initial induction/detoxification and counseling
ST-MAT 626/627 (100%) 554/627 (88%) 502/627 (80%) 361/545 (66%) 215/366 (59%)
LT-MAT 623/623 (100%) 564/623 (91%) N/A 453/541 (84%) 271/385 (70%)
Significance p<.001 p<.001
ST-MAT: BUP/NX dosing during follow-up
26 week induction (optional) 153/440 (35%) 137/153 (90%) 130/153 (85%)
LT-MAT: BUP/NX dosing during follow-up
Weeks 1–4 Weeks 13–16 Weeks 25–28 Weeks 33–36 Weeks 45–48
Received ≥75% of doses2 519/612 (85%) 331/552 (60%) 275/499 (55%) 245/474 (52%) 187/432 (43%)
Received any BUP/NX dose3 590/612 (96%) 416/552 (75%) 345/499 (69%) 294/474 (62%) 239/432 (55%)
Retained in BUP/NX treatment4 597/612 (98%) 449/552 (81%) 370/499 (74%) 317/474 (67%) 239/432 (55%)

ST-MATMAT = Short term medication assisted arm, LT-MAT = Long term medication assisted arm,

1

At the time the study was halted, 1087 had completed the 12 weekly and 751 the 9 monthly counseling sessions

2

Received at least 75% of thrice weekly dosing throughout the period

3

Received any BUP/NX dose in the period

4

Received BUP/NX dose at any point during or after the period